Search Results - "GANJU, V"

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial by Eng, Cathy, Kim, Tae Won, Bendell, Johanna, Argilés, Guillem, Tebbutt, Niall C, Di Bartolomeo, Maria, Falcone, Alfredo, Fakih, Marwan, Kozloff, Mark, Segal, Neil H, Sobrero, Alberto, Yan, Yibing, Chang, Ilsung, Uyei, Anne, Roberts, Louise, Ciardiello, Fortunato, Ahn, JB, Asselah, J, Badarinath, S, Baijal, S, Begbie, S, Berry, S, Canon, JL, Carbone, RG, Cervantes, A, Cha, YJ, Chang, K, Chaudhry, A, Chmielowska, E, Cho, SH, Chu, D, Couture, F, Cultrera, J, Cunningham, D, Van Cutsem, E, Cuyle, PJ, Davies, J, Dowden, S, Dvorkin, M, Ganju, V, Garcia, RV, Kerr, R, Kim, TY, King, K, Kortmansky, J, Kozloff, M, Lam, KO, Lee, J, Lee, AS, Lesperance, B, Luppi, G, Ma, B, Maiello, E, Mandanas, R, Marshall, J, Marx, G, Mullamitha, S, Nechaeva, M, Park, JO, Pavlakis, N, Ponce, CG, Potemski, P, Raouf, S, Reeves, J, Segal, N, Siena, S, Smolin, A, Streb, JO, Strickland, A, Szutowicz-Zielinska, E, Tabernero, JM, Tan, B, Valera, JS, Van den Eynde, M, Vergauwe, P, Vickers, M, Womack, M, Wroblewska, M, Young, R

“…Microsatellite-stable metastatic colorectal cancer is typically unresponsive to immunotherapy. This phase 3 study was designed to assess atezolizumab plus…”
Get full text

The role of canonical and non-canonical Hedgehog signaling in tumor progression in a mouse model of small cell lung cancer by Szczepny, A, Rogers, S, Jayasekara, W S N, Park, K, McCloy, R A, Cochrane, C R, Ganju, V, Cooper, W A, Sage, J, Peacock, C D, Cain, J E, Burgess, A, Watkins, D N

“…Hedgehog (Hh) signaling regulates cell fate and self-renewal in development and cancer. Canonical Hh signaling is mediated by Hh ligand binding to the receptor…”
Get full text

Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C by Price, T.J., Zannino, D., Wilson, K., Simes, R.J., Cassidy, J., Van Hazel, G.A., Robinson, B.A., Broad, A., Ganju, V., Ackland, S.P., Tebbutt, N.C.

“…In an ageing population, a greater proportion of geriatric patients will be considered for systemic chemotherapy. Colorectal cancer (CRC) is a common…”
Get full text

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial by Tebbutt, N C, Cummins, M M, Sourjina, T, Strickland, A, Van Hazel, G, Ganju, V, Gibbs, D, Stockler, M, Gebski, V, Zalcberg, J

“…Background: Docetaxel administered 3-weekly with cisplatin and 5-fluorouracil leads to better survival than does standard therapy in patients with…”
Get full text

Impact of Pretreatment Combined 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography/ Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer: A Prospective Evaluation by Ng, S, David, S, Alamgeer, M, Ganju, V

Get full text

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial by Tebbutt, N C, Parry, M M, Zannino, D, Strickland, A H, Van Hazel, G A, Pavlakis, N, Ganju, V, Mellor, D, Dobrovic, A, Gebski, V J

“…Background: Cetuximab can reverse chemotherapy resistance in colorectal cancer. This study evaluated the efficacy and safety of the combination of docetaxel…”
Get full text

232 Final Results of a Phase II Study of the Combination of Oral Vinorelbine (NVBo), Capecitabine (X) and Trastuzumab (H) in HER2-positive Metastatic Breast Cancer (MBC) by Petruzelka, L, Ganju, V, Conte, P.F, Tubiana-Mathieu, N, Majois, F, Espie, M, Llombart, A, Gil, M. Gil, Villanova, G, Chan, A

Get full text

Policy Implications for Implementing Evidence-Based Practices by Goldman, Howard H., Ganju, Vijay, Drake, Robert E., Gorman, Paul, Hogan, Michael, Hyde, Pamela S., Morgan, Oscar

“…The authors describe the policy and administrative-practice implications of implementing evidence-based services, particularly in public-sector settings. They…”
Get full text

Violence and psychiatric disorder in the community: evidence from the Epidemiologic Catchment Area surveys by Swanson, J W, Holzer, 3rd, C E, Ganju, V K, Jono, R T

“…Data from the Epidemiologic Catchment Area survey were used to examine the relationship between violence and psychiatric disorders among adults living in the…”
Get more information

A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer by Michael, M, Price, T, Ngan, S Y, Ganju, V, Strickland, A H, Muller, A, Khamly, K, Milner, A D, Dilulio, J, Matera, A, Zalcberg, J R, Leong, T

“…Standard chemoradiotherapy with infusional 5FU for locally advanced pancreatic cancer (LAPC) has limited efficacy in this disease. The combination of…”
Get full text

Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting by Sewak, S., Kosmider, S., Ganju, V., Woollett, A., Yeow, E. G., Le, B., Henry, M., Debrincat, M. A., Bell, R.

“…Background: Androgen ablation is the standard treatment for advanced prostate cancer. However, most patients will eventually develop progressive…”
Get full text

Effective treatment of leptomeningeal multiple myeloma with total craniospinal irradiation supported by second allogeneic donor stem cell infusion by QUACH, H, RYAN, G, GANJU, V, PRINCE, H. M

Get full text

BS12PREDICTIVE MARKERS FOR BREAST CANCER NEOADJUVANT CHEMOTHERAPY by Syed, S., Rogers, P. A. W., Ganju, V., Hart, S., Susil, B., Cann, L.

“…Although neoadjuvant chemotherapy (NACT) is routinely used in the management of breast cancer, there is no definitive way of predicting which patients are more…”
Get full text

1622P D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca) by Kondo, S., Yan, D., Ganju, V., Richardson, G., Hou, X., Shan, J., Liu, X., Zhang, Y., Xie, X., Xiang, Z., Shi, Z., Wang, Y., Zhang, L., Yamamoto, N.

Get full text

700P First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors by Cooper, A., Andelkovic, V., Wilkinson, K., Ganju, V., Lundy, J., Hong, M., Airey, S., Meng, L.L., Shen, B., Li, H., Yao, L., Zhang, M., Coward, J.

Get full text

1028P Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors by Day, D., Ganju, V., Chung, K., Si, L., Mao, L., Aghmesheh, M., Hoyer, R., Brewin, K., Zeng, S., Lu, Q., Jiang, C., Ren, F., Wu, X., Guo, J.

Get full text

464 (PB452): Determination of the phase 2 dose of AU-007, an AI-designed human monoclonal antibody that redirects IL-2 to T-effector cells by Wyant, T., McKean, M., Rasco, D., Haydon, A.M., Powderly, J.D., Weickhardt, A.J., Ahern, E.S., De Souza, P., Ganju, V., Hu-Lieskovan, S., Kichenadasse, G., Tang, J., Richards, L., Knickerbocker, A., Amit, I., Ofran, Y., Vasselli, J.

Get full text

5055 High efficacy of the combination of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) in HER2-positive metastatic breast cancer (MBC): updated results of an international phase II trial with a median follow-up of 39 months by Chan, A, Ganju, V, Becquart, D, Conte, P.F, Petruzelka, L, Gil-Gil, M, Morand, M, Vaissiere, N, Villanova, G, Tubiana-Mathieu, N

Get full text

656MO The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated advanced non-breast solid tumors (STs): Results from the global phase I study by Yao, H., Ryu, M.H., Park, J., Voskoboynik, M., Kim, J.H., Liu, K., Barve, M., Acuna-Villaorduna, A., Im, S-A., Roy, A.C., Bai, L-Y., Yen, C-J., Zhang, J., Ganju, V., Wu, L., Yan, M., Bao, L., Zhao, Y., Rong, S., Song, E.

Get full text

First-line trastuzumab (H), oral vinorelbine (NVBo) and capecitabine (X) combination therapy for HER2-positive metastatic breast cancer (MBC): efficacy and safety in a multinational phase II study by Chan, A, Ganju, V, Becquart, D, Conte, P.F, Petruzelka, L, Goedhals, L, Gil Gil, M, Bernardo, G, Villanova, G, Tubiana-Mathieu, N

Get full text